Clinical Trial Update: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) [Phase 3]

View source ↗

Summary

Phase 3 TROPION-Breast03 trial evaluating datopotamab deruxtecan (Dato-DXd) with or without durvalumab versus investigator's choice in Stage I-III triple-negati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING